Developing tumor vaccines, that utilise bodies own immune system, through dc targeting.

Informations projet

DC-TARGETING

N° de convention de subvention: HPMI-CT-2002-00217

Projet clôturé

Date de début 1 Août 2002

Date de fin 31 Juillet 2006

Financé au titre de

• Programme for research, technological development and demonstration on "Improving the human research potential and the socio-economic knowledge base" (1998-2002)

Coût total € 111 000,00

Contribution de l’UE € 111 000,00

Coordonné par

CRUCELL HOLLAND B.V.
Netherlands

Objectif

Ways being explored to use the human immune system to generate enhanced immune responses (therapeutic vaccination) against non-infectious diseases like cancer and diabetes. Dendritic cells are the key players in the initiation of the immune response. For Dendritic Cells to become successful in tumor vaccination, various improvements are required, including the quality of the Dendritic Cells. Crucell Holland BV believes this can only be achieved by targeting to natural occurring Dendritic Cells in vivo. The research area involves the triggering of Dendritic Cells in the right context for differentiation and maturation so the Dendritic Cells can optimally mount immune responses. Monoclonal antibodies are excellent candidates that can serve as such a targeting vehicle. Crucell has used a phage antibody display technology and the proprietary MAbstract technology with blood, tonsil, synovial fluid and monocyte derived Dendritic Cells to obtain a large panel of monoclonal antibodies in vivo or Dendric Cells and monocytes which the aim of using these as a targeting vehicle to deliver tumor associated antigens to in vivo Dendritic Cells. The studies carried out within this research project should provide a major step forward in developing a tumor vaccine that utilizes the body's own immune system to combat various types of cancer.

Champ scientifique (EuroSciVoc)

CORDIS classe les projets avec EuroSciVoc, une taxonomie multilingue des domaines scientifiques, grâce à un processus semi-automatique basé sur des techniques TLN.

• sciences naturelles › sciences biologiques › microbiologie › virologie
• sciences médicales et de la santé › médecine clinique › endocrinologie › diabète
• sciences médicales et de la santé › médecine fondamentale › immunologie
• sciences médicales et de la santé › médecine fondamentale › pharmacologie et pharmacie › produit pharmaceutique › vaccins
• sciences médicales et de la santé › médecine clinique › oncologie

Vous devez vous identifier ou vous inscrire pour utiliser cette fonction

Programme(s)

• FP5-HUMAN POTENTIAL - Programme for research, technological development and demonstration on "Improving the human research potential and the socio-economic knowledge base" (1998-2002)

Thème(s)

Data not available

Appel à propositions

Data not available

Régime de financement

BUR - Bursaries, grants, fellowships

Coordinateur

CRUCELL HOLLAND B.V.

• Contribution de l’UE: Aucune donnée
• Adresse: Archimedesweg 4 ; 2301 CA LEIDEN ; Pays-Bas
• Coût total: Aucune donnée